Actively Recruiting
Study of Intravesical BH011 Treatment for High-Risk Non-Muscle-Invasive Bladder Cancer After BCG Therapy Failure
Led by Zhuhai Beihai Biotech Co., Ltd · Updated on 2025-01-09
48
Participants Needed
6
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and preliminary effectiveness of BH011 in patients with high-risk non-muscle invasive bladder cancer NMIBC who have not responded to Bacillus Calmette-Guerin BCG therapy. This study addresses a critical need for alternatives to cystectomy, a major surgery with significant risks and lifelong impacts, in patients whose cancer has not progressed to muscle invasion or metastasis. The study is conducted as a Phase III, multi-center, open-label trial. Participants will receive BH011 administered directly into the bladder through a urinary catheter, where it remains for one hour. Treatment starts 2 to 8 weeks after transurethral resection of bladder tumor TURBT surgery, with weekly doses for six weeks during the induction phase, followed by monthly doses for twelve months in the maintenance phase. The study includes regular cystoscopy, urine cytology, and biopsy every three months for up to two years to monitor treatment effects. Throughout the study, participants will undergo scheduled evaluations including cystoscopies, biopsies, and urine tests to assess treatment safety and cancer response. Researchers will track treatment-emergent side effects from the first dose until 30 days after the last dose, and measure complete response rates at 3 and 6 months, along with recurrence-free and progression-free survival up to 24 months. The total involvement may last up to two years, with ongoing monitoring for safety and effectiveness.
CONDITIONS
Brief Title
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
Research Team
X
Xiaohua Wei
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here